Cardiovascular Diseases Clinical Trial
Official title:
Broccoli and Vascular Health Study
The participants of this study will be men & women ≥50 years who are deemed to have a 10-30%
risk of developing CVD over the next 10 years. Their risk will be calculated using the Joint
British Societies 2 (JBS2) guidelines on the prevention of CVD in clinical practise
algorithm. This takes into account the participants age, sex, cholesterol values, blood
pressure,family history and their ethnicity (SE Asian or not). The participants will be
randomly assigned to one of two groups with the aid of a computer program called "minim"
which uses their age, sex, BMI and smoking status to determine which broccoli each
participant will consume on the intervention.
Each participant will consume 4 x 100g of their assigned broccoli, each week for 12 weeks on
top of their normal diet. They will be allowed to eat the broccoli whenever they want during
the week, but will be asked to note down when they eat it. A steamer will be provided so
participants can cook their broccoli for the required 4-5 minutes. Participants will be
asked to keep two diet diaries during their time on the intervention, one before they start
the intervention and one towards the end. Blood samples and urine will also be collected,
pre and post intervention, for the analysis of biomarkers of CVD.
This is joint project based at two sites, the Institute of Food (IFR) Research in Norwich
and the University of Reading(UoR), in Reading. Samples from the participants at both sites
will be analysed at IFR, UoR and companies in the United States.
This intervention will take place at two independent sites, The Institute of Food Research's
Human Nutrition Unit (HNU)in Norwich and the Hugh Sinclair Human Nutrition Unit (HSU), at
the University of Reading. The participants recruited from Norwich and Reading will solely
attend the unit in their area and the paper work has been written to reflect this
i.e.separate participant information sheets (PIS). In addition to the tests carried out at
both sites, the Reading cohort will also undergo additional vascular tests, also reflected
in the PIS. Despite the sites being independent, 96 participants will be recruited across
both sites, with the possibility of uneven numbers from each site making up the final
number.
The purpose of this study is to assess whether diet can affect an individuals chances of
developing CVD, as it is one of the biggest killers in the UK. We are particularly
interested in participants who have a 10%-30% risk of developing CVD. We are able to assess
a person's risk with the help of the Joint British Societies 2 guidelines on the prevention
of cardiovascular disease, cardiovascular disease risk prediction chart. These charts take a
number of parameters we obtain from the participant, their age, sex, total cholesterol
concentration, systolic blood pressure (BP), body mass index (BMI), serum high density
lipoprotein concentration, their smoking status and diabetes status and put them into an
algorithm. The result is a risk score out of 100, of a person developing CVD over the next
10 years.
The study will be conducted over two sites, Reading and Norwich, with a principal
investigator assigned to each site. The total number of participants recruited over both
sites will be 96. It may be that uneven numbers are recruited over the two sites e.g. 46 at
one and 50 at another however regardless of the number at each site, 48 participants will be
assigned to each of the two groups. One group will consume 400g of the commercially
available high glucosinolate Beneforté® broccoli each week for 12 weeks and the other will
consume 400g of a standard broccoli, Parthenon for 12 weeks.
As we are assessing the effect of diet on CVD risk, our participants will be screened
initially. Their urine will be tested (urine dipstick test), their height, weight, waist and
hip measurements, BMI, BP will be measured and questions linked to lifestyle choices
(alcohol consumption, smoking status and physical activity) will be asked. A separate
section pertaining to women's health will also be present on the questionnaire.
All participants will be asked to give written informed consent before they can participate
in the intervention study. The Reading cohort will be sent a copy of the consent and medical
declaration forms to read through at home. The forms sent to the homes will be clearly
distinguishable from the real forms as they will have the watermark with "SAMPLE" written
across them.
CVD risk assessment calculator This calculator will be used once the results of the
screening are known. A program devised by the University of Manchester will be used to
calculate the risk our participants have of developing CVD over the next 10 years. This
program is based on the Joint British Societies 2 guidelines on the prevention of CVD risk
prediction charts. For the purposes of this study we would like our participants to fall
into the 10%-30% risk category as most literature suggests people in this range may benefit
from dietary change, without the need for medication, in the most part. The CVD risk scores
will be sent to the participants GP and we will continue to advise our participants to
discuss the results with their GPs if they score >10%.
Genotyping There is evidence to suggest that a person's genetic make-up may affect the way
isothiocyanates (ITCs), one of the active components of broccoli, work. Of the 30,000 genes
found in humans a group of genes associated with the protein glutathione S-transferase M1
(GSTM1) has been shown to affect ITCs after consumption and has been implicated in CVD.
There is evidence to suggest that individuals with a deletion in GSTM1 breakdown the
glucosinolate, from which the ITC sulforaphane is derived, differently to individuals that
have the gene. We also know that glutathione S-transferase theta-1 (GSTT1) may also be
involved in reducing the likelihood of developing CVD.
Along with the GST gene family and their association with cruciferous vegetables, there are
a number of other genes that have been implicated in CVD itself. These include genes
associated with lipid metabolism, thrombosis, leukocyte adhesion and nitric oxide production
and thus blood vessel dilation. This is by no means an exhaustive list and will therefore
remain open to other viable candidates.
Vascular measurements As we age, our arteries stiffen which causes an increase in the
demands of the heart and an increase in blood pressure. This increase in BP can dramatically
increase the risk of heart attack, stroke and heart failure. Arterial stiffness has also
been associated with many of the common risk factors associated with CVD such as age, high
blood pressure, smoking, cholesterol levels and obesity, but importantly, arterial stiffness
has been shown to be an independent predictor of CVD in a large section of society.
There are many ways in which arterial stiffness can be assessed. We will be looking at blood
pressure, which will be very familiar to most participants in our age range (over 50yrs of
age). The only difference being that the participant will wear a cuff for an hour and
readings will be collected every ten minutes.
Another method will be Pulse Wave Analysis (PWA), where a probe will be held against the
neck and the upper thigh to take the measurements for up to a minute at a time. As
participants may not be wholly familiar with this technique, it is hoped that a short video
clip could be shown on a laptop or diagrams/photographs of the technique will be discussed
with the participant at screening.
Restricted conditions prior to study day Before the study day the participants will be asked
to abstain from a number of activities. This will be clearly stated in the PIS.
These include:
1. No alcohol or caffeine for 24 hours before the study day. Participants who consume a
lot of caffeine will be advised that they may suffer from headaches. They will be asked
to tell the study scientist if they needed to take any medication as a consequence.
2. Low fat meal to be consumed the night before the study day. Participants will be asked
to eat a low fat meal from a selected list that we give them. We will ask that the meal
is consumed before 10pm, as the participants will then have to fast for their study
day.
3. Fasting for at least 8 hours. Participants will need to fast for at least 8 hours. This
means that they won't be able to eat or drink anything, apart from water during this
time. They can drink as much water as they feel they need.
4. No heavy exercise the morning of their study day. Participants will be asked not to
engage in any vigorous exercise the morning of their study day. This will be defined as
any activity that causes an increase in heart rate, panting and/or sweating. A
participant who normally cycles will be asked not to on the morning of their study day.
5. No smoking an hour before their study day measurements. All participants that smoke
will be asked to abstain from smoking at least an hour before their study day. We would
also ask that they avoid all passive smoking.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
| Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
| Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
| Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
| Recruiting |
NCT04417387 -
The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
|
||
| Not yet recruiting |
NCT06211361 -
Cardiac Rehabilitation Program in Patients With Cardiovascular Disease
|
N/A | |
| Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
| Recruiting |
NCT04514445 -
The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
|
||
| Enrolling by invitation |
NCT04253054 -
Chinese Multi-provincial Cohort Study-Beijing Project
|
||
| Completed |
NCT03273972 -
INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers
|
N/A | |
| Completed |
NCT03680638 -
The Effect of Antioxidants on Skin Blood Flow During Local Heating
|
Phase 1 | |
| Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
| Completed |
NCT04083846 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed)
|
Phase 1 | |
| Completed |
NCT04083872 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting)
|
Phase 1 | |
| Completed |
NCT03693365 -
Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
|
||
| Completed |
NCT03619148 -
The Incidence of Respiratory Symptoms Associated With the Use of HFNO
|
N/A | |
| Completed |
NCT03466333 -
Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia
|
Phase 2 | |
| Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
| Completed |
NCT05132998 -
Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors
|
N/A | |
| Completed |
NCT05067114 -
Solutions for Atrial Fibrillation Edvocacy (SAFE)
|